AU2009269542A1 - Genetic variants for breast cancer risk assessment - Google Patents

Genetic variants for breast cancer risk assessment Download PDF

Info

Publication number
AU2009269542A1
AU2009269542A1 AU2009269542A AU2009269542A AU2009269542A1 AU 2009269542 A1 AU2009269542 A1 AU 2009269542A1 AU 2009269542 A AU2009269542 A AU 2009269542A AU 2009269542 A AU2009269542 A AU 2009269542A AU 2009269542 A1 AU2009269542 A1 AU 2009269542A1
Authority
AU
Australia
Prior art keywords
seq
breast cancer
allele
risk
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009269542A
Other languages
English (en)
Inventor
Simon Stacey
Patrick Sulem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of AU2009269542A1 publication Critical patent/AU2009269542A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Library & Information Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2009269542A 2008-07-07 2009-07-03 Genetic variants for breast cancer risk assessment Abandoned AU2009269542A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8746 2008-07-07
IS8746 2008-07-07
PCT/IS2009/000008 WO2010004591A2 (en) 2008-07-07 2009-07-03 Genetic variants for breast cancer risk assessment

Publications (1)

Publication Number Publication Date
AU2009269542A1 true AU2009269542A1 (en) 2010-01-14

Family

ID=41110719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009269542A Abandoned AU2009269542A1 (en) 2008-07-07 2009-07-03 Genetic variants for breast cancer risk assessment

Country Status (10)

Country Link
US (1) US8951735B2 (enExample)
EP (1) EP2313525A2 (enExample)
JP (1) JP2011527565A (enExample)
KR (1) KR20110036608A (enExample)
CN (1) CN102144036B (enExample)
AU (1) AU2009269542A1 (enExample)
CA (1) CA2729934A1 (enExample)
IL (1) IL210504A0 (enExample)
NZ (1) NZ590833A (enExample)
WO (1) WO2010004591A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095999A1 (en) * 2010-02-05 2011-08-11 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
WO2012172575A1 (en) * 2011-06-16 2012-12-20 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
CN102643905B (zh) * 2012-04-01 2014-06-11 周宏灏 焦磷酸测序法检测他莫昔芬个体化用药基因多态性的试剂盒及方法
KR101770962B1 (ko) * 2013-02-01 2017-08-24 에스케이텔레콤 주식회사 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치
WO2014119914A1 (ko) * 2013-02-01 2014-08-07 에스케이텔레콤 주식회사 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN103981273B (zh) * 2014-05-30 2017-01-18 复旦大学附属肿瘤医院 一组评估乳腺癌风险的突变基因群及其检测试剂盒
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CN105069322B (zh) * 2015-07-24 2018-01-12 上海尔云信息科技有限公司 疾病易感风险预测装置
HK1259478A1 (zh) 2016-02-12 2019-11-29 Regeneron Pharmaceuticals, Inc. 用於检测异常核型的方法和系统
CN105586427B (zh) * 2016-03-10 2020-06-19 厦门艾德生物医药科技股份有限公司 检测人类brca1和brca2基因突变的引物、试剂盒及方法
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
CN106676169B (zh) * 2016-11-15 2021-01-12 上海派森诺医学检验所有限公司 一种用于乳腺癌易感基因brca1和brca2突变检测的杂交捕获试剂盒及其方法
AU2018213400A1 (en) * 2017-01-24 2019-08-22 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
CN107341347A (zh) * 2017-06-27 2017-11-10 天方创新（北京）信息技术有限公司 基于评分模型对乳腺癌进行风险评分的方法及装置
EP3814521A4 (en) * 2018-06-29 2022-07-27 The Jackson Laboratory SPLICING VARIANTS FOR BREAST CANCER
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
WO2021216363A1 (en) * 2020-04-20 2021-10-28 Myriad Genetics, Inc. Comprehensive polygenic risk prediction for breast cancer
WO2024085660A1 (ko) * 2022-10-18 2024-04-25 제노플랜 인크 질병 발생 위험도 예측 장치 및 방법
TW202440117A (zh) 2023-01-06 2024-10-16 美商愛德亞生物科學公司 使用parg調節劑治療癌症之方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69527585T2 (de) 1994-06-08 2003-04-03 Affymetrix, Inc. Verfahren und Vorrichtung zum Verpacken von Chips
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
AU730633B2 (en) 1996-05-29 2001-03-08 Phillip Belgrader Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
DE10228081A1 (de) * 2002-06-18 2004-01-08 InViTek Gesellschaft für Biotechnik & Biodesign mbH Verfahren zum Nachweis einer gesteigerten Tumorsuszeptibilität
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2006063285A2 (en) * 2004-12-10 2006-06-15 Sequenom, Inc. Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
CN101037690B (zh) * 2006-03-16 2011-07-20 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
CN101641451A (zh) * 2006-10-27 2010-02-03 解码遗传学私营有限责任公司 chr8q24.21上的癌症易感性变体
EP2527466A3 (en) 2007-03-26 2013-05-15 Decode Genetics EHF. Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
US8580501B2 (en) 2007-05-25 2013-11-12 Decode Genetics Ehf. Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment

Also Published As

Publication number Publication date
KR20110036608A (ko) 2011-04-07
WO2010004591A2 (en) 2010-01-14
CN102144036A (zh) 2011-08-03
IL210504A0 (en) 2011-03-31
CA2729934A1 (en) 2010-01-14
US20110294673A1 (en) 2011-12-01
JP2011527565A (ja) 2011-11-04
US8951735B2 (en) 2015-02-10
WO2010004591A3 (en) 2010-03-18
CN102144036B (zh) 2014-07-16
NZ590833A (en) 2013-01-25
EP2313525A2 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
US8580501B2 (en) Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
US8951735B2 (en) Genetic variants for breast cancer risk assessment
US20110117545A1 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2247755B1 (en) Susceptibility variants for lung cancer
US20110269143A1 (en) Genetic Variants as Markers for Use in Urinary Bladder Cancer Risk Assessment, Diagnosis, Prognosis and Treatment
CA2729931A1 (en) Genetic variants predictive of cancer risk in humans
US20110020320A1 (en) Genetic Variants Contributing to Risk of Prostate Cancer
WO2013065072A1 (en) Risk variants of prostate cancer
AU2008331069B2 (en) Genetic variants on CHR HQ and 6Q as markers for prostate and colorectal cancer predisposition
WO2010131268A1 (en) Genetic variants for basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma
WO2011095999A1 (en) Genetic variants for predicting risk of breast cancer

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application